Q4 Revenues up, but Losses Widen for Exelixis | GenomeWeb

NEW YORK, Feb. 17 (GenomeWeb News) - Exelixis today reported an increase in revenues for the quarter ended Dec. 31, 2003, along with higher net losses and rising R&D expenses.

Exelixis posted total revenues of $13.8 million for the fourth quarter, up from $12.5 million in the same period of 2002.

The company's net loss widened to $23.3 million from $20.9 million in the fourth quarter of 2002.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.